Collegium Pharmaceutical, Inc: Form 10-Q for the period ended Sep 30, 2022
Filed with the SEC on Nov 3, 2022 and accepted by EDGAR at Nov 3, 2022, 16:10 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-07-01 to 2022-09-30 | $127.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2022-01-01 to 2022-09-30 | $334.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2022-07-01 to 2022-09-30 | $68.2m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2022-01-01 to 2022-09-30 | $174.6m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2022-07-01 to 2022-09-30 | $58.8m | us-gaap:GrossProfit |
| Gross profit | 9 months2022-01-01 to 2022-09-30 | $159.7m | us-gaap:GrossProfit |
| Research and development | 9 months2022-01-01 to 2022-09-30 | $4.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2022-07-01 to 2022-09-30 | $38.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2022-01-01 to 2022-09-30 | $134.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2022-07-01 to 2022-09-30 | $20.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2022-01-01 to 2022-09-30 | $21.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2022-07-01 to 2022-09-30 | $19.0m | us-gaap:InterestExpense |
| Interest expense | 9 months2022-01-01 to 2022-09-30 | $42.6m | us-gaap:InterestExpense |
| Income tax | 3 months2022-07-01 to 2022-09-30 | $975.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2022-01-01 to 2022-09-30 | −$3.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-07-01 to 2022-09-30 | $457.0k | us-gaap:NetIncomeLoss |
| Net income | 9 months2022-01-01 to 2022-09-30 | −$17.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-07-01 to 2022-09-30 | $0.01 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2022-01-01 to 2022-09-30 | −$0.52 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-07-01 to 2022-09-30 | $0.01 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2022-01-01 to 2022-09-30 | −$0.52 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-07-01 to 2022-09-30 | 34,570,319 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2022-01-01 to 2022-09-30 | 33,912,832 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2022-01-01 to 2022-09-30 | $57.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2022-01-01 to 2022-09-30 | $682.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months2022-01-01 to 2022-09-30 | $6.4m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2022-09-30 | $134.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-09-30 | $405.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-09-30 | $1.20bn | us-gaap:Assets |
| Current liabilities | At period end2022-09-30 | $414.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-09-30 | $1.00bn | us-gaap:Liabilities |
| Shareholders' equity | At period end2022-09-30 | $197.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-22-016241. Last ingested by Listed: Nov 5, 2026, 12:06 ET. Listed shows no prices and gives no investment advice.